Israeli medical device company Ornim Inc announced the completion of the $20 million Series C financing led by Shanghai Hongshi Medical Health Industry Fund.
Ornim has entered the commercial phase, and its c-FLOW platform is a non-invasive medical device that monitors the blood flow of the human brain and other vital tissues in real time. c-FLOW has been approved in the US and has applied for registration in China. It is expected to be approved for listing in China in the second half of 2017.
OrbiMed, GE Ventures and other existing investors are also involved in this round of financing. In 2014 OrbiMed led a $10 million investment in Ornim.
Ornim plans to use the latest round of financing to accelerate the expansion of commercial operations in the United States and to promote the c-FLOW platform to obtain approval from the China Food and Drug Administration.
Ornim specializes in the development and sales of tissue and cerebral blood flow medical devices. Based on the company's proprietary c-FLOW platform technology, the c-FLOW platform combines near-infrared and ultrasonic pulses to accurately measure changes in blood flow in the brain and muscle tissue.
Shaanxi Haibo Biotechnology Co., Ltd. specializes in the research, production and sales of natural plant extracts used in the cosmetic raw material industry. The main products of this category are Ellagic Acid, Ferulic Acid, etc.
which are professionally used in the research, production and sales of cosmetic raw materials.
It is used in the manufacture of fragrances, cosmetics, detergents, plasticizers, etc., and as a stationary solution for gas chromatography.
Anti-Allergy Material,Salicylic Acid,Ellagic Acid,Ferulic Acid
SHAANXI HAIBO BIOTECHNOLOGY CO., LTD , https://www.rozenbio.com